SynthesisAesthetic plastic surgery2026
Evaluation of the Safety and Efficacy of Tranexamic Acid Use in Blepharoplasty: A Systematic Review of Randomized Controlled Trials.
Synthesis in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTXA is garnering increasing attention for aesthetic periorbital procedures for its ability to reduce postoperative ecchymosis and bruising. The aim of this systematic review is to compile the current literature evidence on the effectiveness and safety of TXA in blepharoplasty.
methodsFollowing PRISMA guidelines, this systematic review identified articles from PubMed, MEDLINE, Cochrane, and EMBASE databases up to October 4th, 2024, aiming to assess the efficacy of TXA in reducing bleeding and edema in patients undergoing blepharoplasty.
resultsFive studies were included, comprising a total of 604 patients who underwent blepharoplasty with TXA administration. TXA concentrations ranged from 50mg/mL to 100mg/mL locally, and 1g IV. Three studies reported a reduction in intra-operative bleeding with local TXA, with one study demonstrating statistical difference (p < 0.001). Statistically significant reduction in time to achieve hemostasis with IV TXA (p < 0.0001) and reductions in ecchymosis at 1 week postoperatively (p = 0.04) were reported. One study reported a statistically significant reduction in edema scores at 1 (p = 0.002) and 7 days (p = 0.01) postoperatively. Procedure times remained unchanged or reduced, with one study showing statistical significance with both IV (p = 0.003) and local (p = 0.03) TXA. None of the studies reported any infections or wound complications.
conclusionTXA administration appears to reduce intra-operative bleeding and postoperative ecchymosis and edema after blepharoplasty with no significant complications reported with IV and local administrations of TXA in the included studies. The development of standardized protocols for TXA administration highlighting the optimal dosage, timing, and administration routes is recommended. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
42082663What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.